STXS on NYSE
Stereotaxis, Inc.
Stereotaxis, Inc. All other trademarks that appear in this report are the property of their respective owners.4 From its latest annual report
$1.03 down 0.02 (1.90%)Price as of Oct 15, 2026 at 17:33 UTC
Last updated Oct 19, 2026.
Overview
Compare with electroCore, Inc., PRECISION OPTICS CORPORATION, INC. or IRIDEX CORP, or pick any stock.
- TickerSTXS on NYSE1
- IndustryElectromedical & Electrotherapeutic Apparatus1
- HeadquartersSt.Louis, Missouri1
- Incorporated inDE3
- Business address710 N Tucker Blvd, Ste 110, St.Louis, Mo 631013
- Filer categoryNon-accelerated filer, Smaller reporting company3
- Legal formCorporation
See how the biggest companies compare on our leaderboards
Stereotaxis, Inc. All other trademarks that appear in this report are the property of their respective owners.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Disposables Service and Accessories brought in 68% of the revenue Stereotaxis, Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| Disposables Service and Accessories | $18.3M | $22.2M |
| Systems | $8.6M | $10.2M |
Regions
Outside the United States brought in 60% of the revenue Stereotaxis, Inc. broke down this way in fiscal 2025.
Regions by year
| Regions | 2024 | 2025 |
|---|---|---|
| Outside the United States | $13.5M | $19.5M |
| United States | $13.4M | $12.9M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue47¢$15.3M
- Research and development29¢$9.4M
- Other costs24¢$7.7M
Out of $32.4M in revenue.5 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total revenue | $32.4M | $26.9M |
| Total cost of revenue | $15.3M | $12.3M |
| Gross margin | $17.1M | $14.6M |
| Research and development | $9.4M | $9.8M |
| Sales and marketing | $12.4M | $12.4M |
| General and administrative | $17.8M | $17.2M |
| Other | -$492.0K | |
| Total operating expenses | $39.2M | $39.3M |
| Operating loss | -$22.1M | -$24.7M |
| Other income | $2.0K | |
| Interest income, net | $467.0K | $694.0K |
| Net loss | -$21.6M | -$24.0M |
| Cumulative dividend on convertible preferred stock | -$1.3M | -$1.3M |
| Net loss attributable to common stockholders | -$22.9M | -$25.4M |
| Basic | -$0.25 | -$0.30 |
| Diluted | -$0.25 | -$0.30 |
| Basic | 91.0M shares | 85.2M shares |
| Diluted | 91.0M shares | 85.2M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $13.4M | $12.2M | |
| Restricted cash - current | $219.0K | ||
| Accounts receivable, net of allowance of $541 and $582 at 2025 and 2024, respectively | $5.8M | $3.8M | |
| Insurance receivable | $4.3M | ||
| Inventories, net | $9.6M | $8.3M | |
| Prepaid expenses and other current assets | $698.0K | $1.8M | |
| Total current assets | $33.8M | $26.4M | |
| Property and equipment, net | $3.0M | $3.6M | |
| Goodwill | $3.8M | $3.8M | |
| Intangible assets, net | $6.4M | $7.4M | |
| Operating lease right-of-use assets | $4.9M | $5.5M | |
| Prepaid and other non-current assets | $278.0K | $107.0K | |
| Total assets | $52.3M | $46.7M | |
| Accounts payable | $4.8M | $5.7M | |
| Accrued liabilities | $2.1M | $2.9M | |
| Accrued legal liabilities | $4.3M | ||
| Deferred revenue | $5.7M | $6.8M | |
| Current contingent consideration | $4.9M | $5.6M | |
| Current portion of operating lease liabilities | $642.0K | $570.0K | |
| Total current liabilities | $22.4M | $21.6M | |
| Long-term deferred revenue | $555.0K | $2.1M | |
| Long term contingent consideration | $4.7M | $6.1M | |
| Operating lease liabilities | $4.8M | $5.4M | |
| Other liabilities | $1.1M | $64.0K | |
| Total liabilities | $33.5M | $35.3M | |
| Convertible preferred stock, Series A, par value $0.001; 10,000,000 shares authorized; 21,008 and 21,458 shares outstanding at 2025 and 2024, respectively | $5.2M | $5.4M | |
| Common stock, par value $0.001; 300,000,000 shares authorized, 95,339,628 and 85,326,557 shares issued at 2025 and 2024, respectively | $95.0K | $85.0K | |
| Additional paid in capital | $597.0M | $567.9M | |
| Treasury stock, 4,015 shares at 2025 and 2024 | -$206.0K | -$206.0K | |
| Accumulated deficit | -$583.4M | -$561.7M | |
| Total stockholders equity | $13.5M | $6.1M | $16.3M |
| Total liabilities and stockholders equity | $52.3M | $46.7M | |
| Accounts receivable, allowance | $541.0K | $582.0K | |
| Series A convertible preferred stock, par value | $0.00 | $0.00 | |
| Series A convertible preferred stock, shares authorized | 10.0M shares | 10.0M shares | |
| Series A convertible preferred stock, shares outstanding | 21.0K shares | 21.5K shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 300.0M shares | 300.0M shares | |
| Common stock, shares issued | 95.3M shares | 85.3M shares | |
| Treasury stock, shares | 4.0K shares | 4.0K shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $13.4M | $12.2M | |
| Restricted cash - current | $219.0K | ||
| Accounts receivable, net of allowance of $541 and $582 at 2025 and 2024, respectively | $5.8M | $3.8M | |
| Insurance receivable | $4.3M | ||
| Inventories, net | $9.6M | $8.3M | |
| Prepaid expenses and other current assets | $698.0K | $1.8M | |
| Total current assets | $33.8M | $26.4M | |
| Property and equipment, net | $3.0M | $3.6M | |
| Goodwill | $3.8M | $3.8M | |
| Intangible assets, net | $6.4M | $7.4M | |
| Operating lease right-of-use assets | $4.9M | $5.5M | |
| Prepaid and other non-current assets | $278.0K | $107.0K | |
| Total assets | $52.3M | $46.7M | |
| Accounts payable | $4.8M | $5.7M | |
| Accrued liabilities | $2.1M | $2.9M | |
| Accrued legal liabilities | $4.3M | ||
| Deferred revenue | $5.7M | $6.8M | |
| Current contingent consideration | $4.9M | $5.6M | |
| Current portion of operating lease liabilities | $642.0K | $570.0K | |
| Total current liabilities | $22.4M | $21.6M | |
| Long-term deferred revenue | $555.0K | $2.1M | |
| Long term contingent consideration | $4.7M | $6.1M | |
| Operating lease liabilities | $4.8M | $5.4M | |
| Other liabilities | $1.1M | $64.0K | |
| Total liabilities | $33.5M | $35.3M | |
| Convertible preferred stock, Series A, par value $0.001; 10,000,000 shares authorized; 21,008 and 21,458 shares outstanding at 2025 and 2024, respectively | $5.2M | $5.4M | |
| Common stock, par value $0.001; 300,000,000 shares authorized, 95,339,628 and 85,326,557 shares issued at 2025 and 2024, respectively | $95.0K | $85.0K | |
| Additional paid in capital | $597.0M | $567.9M | |
| Treasury stock, 4,015 shares at 2025 and 2024 | -$206.0K | -$206.0K | |
| Accumulated deficit | -$583.4M | -$561.7M | |
| Total stockholders equity | $13.5M | $6.1M | $16.3M |
| Total liabilities and stockholders equity | $52.3M | $46.7M | |
| Accounts receivable, allowance | $541.0K | $582.0K | |
| Series A convertible preferred stock, par value | $0.00 | $0.00 | |
| Series A convertible preferred stock, shares authorized | 10.0M shares | 10.0M shares | |
| Series A convertible preferred stock, shares outstanding | 21.0K shares | 21.5K shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 300.0M shares | 300.0M shares | |
| Common stock, shares issued | 95.3M shares | 85.3M shares | |
| Treasury stock, shares | 4.0K shares | 4.0K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$21.6M | -$24.0M |
| Depreciation | $626.0K | $587.0K |
| Amortization of intangibles | $929.0K | $382.0K |
| Loss on revaluation of contingent consideration | $2.2M | $1.8M |
| Non-cash lease expense | $1.0K | $14.0K |
| Stock-based compensation | $9.9M | $10.3M |
| Accounts receivable | -$2.0M | $691.0K |
| Inventories | -$1.2M | $677.0K |
| Prepaid expenses and other current assets | $1.2M | -$146.0K |
| Other assets | -$170.0K | $29.0K |
| Accounts payable | -$880.0K | $758.0K |
| Accrued liabilities | $188.0K | -$99.0K |
| Deferred revenue | -$2.6M | $574.0K |
| Other liabilities | -$13.0K | $21.0K |
| Net cash used in operating activities | -$13.7M | -$8.5M |
| Purchase of property and equipment | -$93.0K | -$34.0K |
| Cash acquired in business acquisitions | $108.0K | |
| Net cash (used in) provided by investing activities | -$93.0K | $74.0K |
| Proceeds from issuance of stock | $15.7M | $297.0K |
| Equity issuance costs | -$893.0K | |
| Net cash provided by financing activities | $14.8M | $297.0K |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | $985.0K | -$8.1M |
| Fair value of shares of common stock issued for contingent consideration earnouts | $4.3M |
No quarter-by-quarter statement was filed.
Leadership
Who has led Stereotaxis, Inc., and when. Pick a name to see everywhere that person has worked.
Chief financial officer
Chief operating officer
- Chief executive officerWilliam C. Mills Iii. Apr 16, 2013 to Apr 15, 201613
- Chief executive officerMichael P. Kaminski Jun 4, 2009 to Apr 3, 201314
- Chief executive officerBevil J. Hogg Feb 24, 2006 to Dec 15, 200815
- PresidentMichael P. Kaminski Aug 27, 2007 to Apr 3, 201316
- PresidentBevil J. Hogg Feb 24, 2006 to Feb 9, 200715
- Chief financial officerKimberly R. Peery Oct 2, 2019 to now17
- Chief financial officerMartin C. Stammer Mar 1, 2013 to Mar 5, 201918
- Chief financial officerSamuel M. Duggan Ii. Oct 5, 2011 to Oct 3, 201219
- Chief financial officerDaniel J. Johnston Nov 17, 2009 to Feb 17, 201120
- Chief financial officerJames M. Stolze Feb 24, 2006 to Nov 17, 200921
- Chief operating officerMichael P. Kaminski Feb 24, 2006 to Dec 17, 200822
Board members and other officers (34)
- Section 16 OfficerPaul Brathwaite Aug 6, 2015 to Feb 13, 201823
- Corporate Controller and PAOMartin C. Stammer Aug 25, 2011 to Oct 12, 201124
- VP, Human ResourcesDavid Giffin Jun 4, 2010 to Mar 30, 201725
- Senior VP, Marketing and BDFrank Cheng Jun 4, 2010 to Aug 25, 201626
- Sr. VP, Gen. Counsel, and Sec.Karen Witte Duros Nov 5, 2010 to Mar 29, 201827
- Sr. VP, Marketing & Bus. Dev.Kevin T. Shifrin Mar 27, 2008 to Nov 19, 200828
- Sr. V.P., North AmericaLouis T. Ruggiero Jun 4, 2008 to Jun 12, 200929
- Sr. VP, Business DevelopmentLuke Harada Sep 10, 2007 to Sep 10, 200730
- Sr. VP, Research & DevelopmentDouglas Michael Bruce Feb 24, 2006 to Feb 16, 201231
- VP, Regulatory & QualityMelissa Walker Feb 24, 2006 to Feb 19, 201032
- Chief Medical OfficerRuchir Sehra Feb 24, 2006 to Jun 16, 200633
- Board memberNachum Shamir Jul 22, 2024 to now34
- Board memberPaul J. Isaac Aug 16, 2023 to now35
- Board memberCuret Myriam Jul 28, 2021 to now36
- Board memberRoss B. Levin Jun 5, 2018 to now37
- Board memberNathan Fischel Feb 7, 2017 to now38
- Board memberArun Swarup Menawat Oct 3, 2016 to now39
- Board memberEuan Thomson Oct 24, 2012 to May 25, 201640
- Board memberJoseph D. Keegan Mar 21, 2011 to May 25, 201641
- Board memberDouglas Michael Bruce Oct 12, 2011 to Oct 12, 201142
- Board memberMichael P. Kaminski Dec 15, 2008 to Apr 3, 201343
- Board memberEric N. Prystowsky Feb 9, 2007 to May 25, 201644
- Board memberWilliam C. Mills Iii. Jan 11, 2006 to Apr 15, 201645
- Board memberBevil J. Hogg Feb 24, 2006 to Mar 15, 201015
- Board memberRobert J. Messey May 16, 2006 to Jan 2, 202446
- Board memberAbhi Acharya May 30, 2006 to Mar 5, 200847
- Board memberAbhijeet J. Lele May 30, 2006 to May 28, 201048
- Board memberChristopher D. Alafi May 30, 2006 to May 14, 201249
- Board memberDavid Benfer May 30, 2006 to now50
- Board memberFred A. Middleton May 30, 2006 to Mar 5, 201851
- Board memberGregory R. Johnson May 30, 2006 to Dec 11, 200752
- Board memberRalph G. Dacey Jr. May 30, 2006 to Jun 2, 200853
- Board memberWilliam M. Kelley May 30, 2006 to Aug 24, 201254
- General counselKevin M. Barry Nov 7, 2018 to Mar 5, 201955
Named in SEC Form D filings
People the company listed in its private-offering notices.
Timeline
Filings
201 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 34 major events, 92 insider forms, 7 large holders, 1 private raises, 46 other. The latest 20:
- Aug 19, 2026SCHEDULE 13G EDGAR
- Aug 13, 2026EFFECT EDGAR
- Aug 13, 2026EFFECT EDGAR
- Aug 13, 2026424B3 EDGAR
- Aug 13, 2026424B3 EDGAR
- Aug 12, 202610-Q EDGAR
- Aug 11, 20268-K EDGAR
- Jul 16, 20268-K EDGAR
- Jul 15, 2026S-3 EDGAR
- Jul 15, 2026S-3 EDGAR
- Jul 9, 20268-K EDGAR
- Jul 1, 20264 EDGAR
- Jul 1, 20264 EDGAR
- Jul 1, 20264 EDGAR
- Jul 1, 20264 EDGAR
- Jul 1, 20264 EDGAR
- Jul 1, 20264 EDGAR
- May 29, 2026SD EDGAR
- May 15, 2026SCHEDULE 13G/A EDGAR
- May 15, 20268-K EDGAR
The 201 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
47 open-market trades by officers, directors and large owners since October 2021: 47 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 17, 2025 | Isaac Paul JDirector | Buy | 10,000 | $2.18 | $21.8K | Form 4 |
| Nov 14, 2025 | Isaac Paul JDirector | Buy | 20,000 | $2.24 | $44.8K | Form 4 |
| Mar 10, 2025 | Isaac Paul JDirector | Buy | 38,000 | $1.81 | $68.8K | Form 4 |
| Mar 7, 2025 | Isaac Paul JDirector | Buy | 1,489 | $1.79 | $2.7K | Form 4 |
| Mar 6, 2025 | Isaac Paul JDirector | Buy | 23,299 | $1.81 | $42.2K | Form 4 |
| Aug 20, 2024 | Isaac Paul JDirector | Buy | 442 | $1.88 | $831 | Form 4 |
| Aug 19, 2024 | Isaac Paul JDirector | Buy | 812 | $1.88 | $1.5K | Form 4 |
| Aug 15, 2024 | Isaac Paul JDirector | Buy | 8,095 | $1.90 | $15.4K | Form 4 |
| Jun 14, 2024 | Isaac Paul JDirector | Buy | 7,000 | $1.86 | $13.0K | Form 4 |
| May 31, 2024 | Isaac Paul JDirector | Buy | 1,000 | $1.96 | $2.0K | Form 4 |
| May 29, 2024 | Isaac Paul JDirector | Buy | 3,026 | $1.90 | $5.7K | Form 4 |
| May 28, 2024 | Isaac Paul JDirector | Buy | 6,000 | $1.91 | $11.5K | Form 4 |
| Dec 15, 2023 | Isaac Paul JDirector | Buy | 11,060 | $1.72 | $19.0K | Form 4 |
| Nov 30, 2023 | Isaac Paul JDirector | Buy | 2,808 | $1.56 | $4.4K | Form 4 |
| Nov 22, 2023 | Isaac Paul JDirector | Buy | 18 | $1.50 | $27 | Form 4 |
| Nov 21, 2023 | Isaac Paul JDirector | Buy | 6,000 | $1.53 | $9.2K | Form 4 |
| Nov 20, 2023 | Isaac Paul JDirector | Buy | 6,000 | $1.54 | $9.2K | Form 4 |
| Nov 17, 2023 | Isaac Paul JDirector | Buy | 6,000 | $1.55 | $9.3K | Form 4 |
| Nov 16, 2023 | Isaac Paul JDirector | Buy | 15,000 | $1.51 | $22.6K | Form 4 |
| Nov 15, 2023 | Isaac Paul JDirector | Buy | 20,000 | $1.44 | $28.8K | Form 4 |
All 47 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Daniel Louis KaufmanSCHEDULE 13G, 1 filing Aug 19, 202657
- Lagoda Investment Management, L.P.SCHEDULE 13G/A, 2 filings May 15, 2025 to May 15, 202658
- Redmile Group, LLCSC 13G/A, 3 filings Feb 14, 2022 to Feb 14, 202459
- Arbiter Partners Capital Management LLCSC 13G/A, 1 filing Feb 3, 202260
Money raised
Private offerings the company reported to the SEC on Form D.
- Jul 31, 2024Raised $3 million in a private offering of equity Form D: 1 investor so far Form D
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2Yahoo FinanceSTXS quote
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16SEC EDGARMichael P. Kaminski, President
- 17
- 18
- 19
- 20
- 21
- 22
- 23SEC EDGARPaul Brathwaite, Section 16 Officer
- 24
- 25SEC EDGARDavid Giffin, VP, Human Resources
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33SEC EDGARRuchir Sehra, Chief Medical Officer
- 34SEC EDGARNachum Shamir, Board member
- 35SEC EDGARPaul J. Isaac, Board member
- 36SEC EDGARCuret Myriam, Board member
- 37SEC EDGARRoss B. Levin, Board member
- 38SEC EDGARNathan Fischel, Board member
- 39SEC EDGARArun Swarup Menawat, Board member
- 40SEC EDGAREuan Thomson, Board member
- 41SEC EDGARJoseph D. Keegan, Board member
- 42SEC EDGARDouglas Michael Bruce, Board member
- 43SEC EDGARMichael P. Kaminski, Board member
- 44SEC EDGAREric N. Prystowsky, Board member
- 45SEC EDGARWilliam C. Mills Iii., Board member
- 46SEC EDGARRobert J. Messey, Board member
- 47SEC EDGARAbhi Acharya, Board member
- 48SEC EDGARAbhijeet J. Lele, Board member
- 49SEC EDGARChristopher D. Alafi, Board member
- 50SEC EDGARDavid Benfer, Board member
- 51SEC EDGARFred A. Middleton, Board member
- 52SEC EDGARGregory R. Johnson, Board member
- 53SEC EDGARRalph G. Dacey Jr., Board member
- 54SEC EDGARWilliam M. Kelley, Board member
- 55SEC EDGARKevin M. Barry, General counsel
- 56
- 57
- 58
- 59
- 60